AstraZeneca Strikes Landmark Deal with Trump Administration to Slash Medicaid Drug Prices
WASHINGTON – In a significant move impacting prescription drug costs for millions of Americans, pharmaceutical titan AstraZeneca has reached an agreement with the Trump administration to substantially lower the price of its medications for Medicaid beneficiaries. This landmark deal, announced Friday by President Donald Trump in the Oval Office alongside AstraZeneca CEO Pascal Soriot, marks the second such pact with a major drug manufacturer, following a similar accord with Pfizer last month. The agreements aim to address the long-standing issue of high drug prices in the United States, utilizing the administration’s “most-favored-nation” pricing strategy and the implicit threat of steep tariffs.
The Landmark Agreement
Under the terms of the new agreement, AstraZeneca will adopt “most-favored-nation” pricing for all its prescription drugs covered by Medicaid. This means the company commits to charging the U.S. government’s healthcare program for low-income individuals no more than the lowest price offered for the same drugs in other developed nations. Furthermore, this pricing guarantee will extend to all newly launched AstraZeneca medications, a crucial provision that could prevent future price escalations.
Trump’s Stance and Negotiations
President Trump highlighted the historical disparity in drug pricing, stating, “For many years, Americans have paid the highest prices in the world for prescription drugs, by far.” He expressed optimism that these new deals could drive prices down to “the lowest price anywhere in the world.” The administration’s aggressive stance, including the threat of tariffs on pharmaceutical imports, played a pivotal role in these negotiations. AstraZeneca CEO Pascal Soriot candidly admitted that Trump and his team “really kept me up at night” during the intense discussions.
Executive Order Context
This agreement aligns with an executive order signed by President Trump in May, which mandated drugmakers either voluntarily reduce prices or face new limits on government payments. The order set a clear deadline for compliance, signaling the administration’s intent to compel price reductions across the pharmaceutical industry. The deal with AstraZeneca, and previously with Pfizer, demonstrates the administration’s strategy to pressure individual companies into compliance.
Major Investment in U.S. Operations
Beyond price reductions, AstraZeneca also unveiled a substantial commitment to its U.S. operations. The Cambridge, United Kingdom-based company announced plans for a new $4.5 billion manufacturing plant near Charlottesville, Virginia. Republican Governor Glenn Youngkin joined the Oval Office announcement, praising the groundbreaking for the new facility. This plant is a cornerstone of AstraZeneca’s broader strategy to invest $50 billion in the U.S. by 2030, projecting the creation of at least 3,600 new domestic jobs “just to begin with,” according to President Trump. The company anticipates generating $80 billion in total revenue by 2030, with half of that projected to come from the U.S. market.
Impact on Key Medications
AstraZeneca’s portfolio includes several high-impact cancer treatments, such as Tagrisso for lung cancer, Lynparza for ovarian cancer, and Calquence for chronic lymphocytic leukemia. These three drugs alone accounted for over $7.5 billion in U.S. sales last year, underscoring the potential financial impact of the new pricing agreement.
Strategic Realignment
The announcement comes months after AstraZeneca canceled plans to expand a vaccine manufacturing plant in its home country, citing reduced government financial support as a contributing factor. The timing of these U.S. commitments, following the tariff threats, suggests a strategic realignment by the pharmaceutical giant.
Introducing TrumpRX.gov
The Trump administration also unveiled a landing page for its forthcoming website, TrumpRX.gov, envisioned as a platform where consumers can directly purchase prescription drugs from manufacturers. Officials confirmed that both Pfizer and AstraZeneca will offer medications through this new portal. The website’s landing page, prominently featuring images of President Trump, promises a “Coming Soon” launch in January 2026 and notes its design by “The National Design Studio,” a government hub established by executive order and led by Airbnb co-founder Joe Gebbia.
Political Context
Despite one of AstraZeneca’s drugs already being subject to price reductions under a Medicare negotiating strategy implemented by the Biden administration, Trump vehemently asserted that Democrats should not “get credit” for these drug price initiatives, anticipating attempts by the opposing party to claim success. This highlights the contentious political landscape surrounding healthcare costs, a perennial issue in American politics.
Associated Press writers Tom Murphy and Michelle L. Price contributed to this report.
